Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02215161 · ClinicalTrials.gov registry record · Phase 2
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT02215161 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 14 participants.
The verdict
NCT02215161, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This phase II trial studies selinexor in treating patients with prostate cancer that has spread to other parts of the body (metastatic), keeps growing even when the amount of testosterone in the body is reduced to very low levels (castration-resistant), and did not respond to treatment (refractory) with abiraterone acetate and/or enzalutamide. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-09-02 |
| Est. Completion | 2018-04-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02215161
The ClinicalTrials.gov registry entry for NCT02215161 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Selinexor is the first listed.
NCT02215161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02215161 about?
NCT02215161 is a clinical study titled "Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer". This phase II trial studies selinexor in treating patients with prostate cancer that has spread to other parts of the body (metastatic), keeps growing even when the amount of testosterone in the body is reduced to very low levels (castration-resistant), and did not respond to treatment (refractory) ...
What is the current status of trial NCT02215161?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2014-09-02. Estimated completion is 2018-04-02.
What interventions are being tested in trial NCT02215161?
The interventions under investigation include: Selinexor (DRUG).
Who is sponsoring clinical trial NCT02215161?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.